GAITHERSBURG, Md., June 19 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that its senior management will host a Business
Review Meeting on June 27, 2003 at the Gaithersburg Marriott Washingtonian
Center in Gaithersburg, Maryland. At the meeting, MedImmune's senior
executives will review the company's development pipeline and marketed
products, including an overview of its launch plans for FluMist(TM) (Influenza
Virus Vaccine Live, Intranasal), the first influenza vaccine delivered as a
nasal mist available in the United States for healthy people, which was
recently approved for marketing by the U.S. Food and Drug Administration.
Investors and the general public may listen to a live webcast of the
meeting via the Investor Relations page on MedImmune's website at
www.medimmune.com. Windows Media is needed to access the presentation, which
can be downloaded prior to the meeting from MedImmune's website. An archive
of the meeting will be available until July 11, 2003.
MedImmune is a leading biotechnology company focused on researching,
developing and commercializing products to prevent or treat infectious
disease, autoimmune disease and cancer. MedImmune actively markets three
products, Synagis(R) (palivizumab), Ethyol(R) (amifostine) and CytoGam(R)
(cytomegalovirus immune globulin intravenous (human)), and has additional
products in clinical testing. MedImmune employs approximately 1,700 people,
is headquartered in Gaithersburg, Maryland, and has additional operations in
Frederick, Maryland, as well as Pennsylvania, California, the United Kingdom
and the Netherlands. For more information on MedImmune, visit the company's
website at www.medimmune.com.
This announcement and the event described in this announcement may
contain, in addition to historical information, certain forward-looking
statements that involve risks and uncertainties. Such statements reflect
management's current views and are based on certain assumptions. Actual
results could differ materially from those currently anticipated as a result
of a number of factors, including risks and uncertainties discussed in the
company's filings with the U.S. Securities and Exchange Commission. The
company is developing several products for potential future marketing. There
can be no assurance that such development efforts will succeed, that such
products will receive required regulatory clearance or that, even if such
regulatory clearance were received, such products would ultimately achieve
SOURCE MedImmune, Inc.
/CONTACT: Investors: William Roberts, +1-301-527-4358, or John Filler,
+1-240-632-4086, or Media: Jamie Lacey, +1-240-632-4035, all of MedImmune,
/Web site: http://www.medimmune.com/
CO: MedImmune, Inc.
IN: MTC BIO HEA
-- DCTH035 --
0792 06/19/2003 13:00 EDT http://www.prnewswire.com